Delivery Order SPE2DB22D3004-SPE2DB23FRE69

Award Date 9/5/23
Potential Completion Date 9/6/23
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $5,076 to Amerisourcebergen Drug Corporation for the supply of 100 Vyvanse 30 mg capsules. The place of performance for this order is Amerisourcebergen's corporate office location in Conshohocken, Pennsylvania. The period of performance is August 16-17, 2023. This delivery order was issued against an existing DLA pharmaceutical supply contract vehicle to fulfill requirements for Vyvanse, a Schedule...
The Defense Logistics Agency awarded a $3,017 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 capsules of Vyvanse 10 mg. The order is to be fulfilled from Amerisourcebergen's facility located in Conshohocken, Pennsylvania by July 14, 2023. Vyvanse, a Schedule II controlled substance, is used to treat attention deficit hyperactivity disorder and binge eating disorder. This delivery order was issued against an existing DLA pharmaceuticals contract vehicle to supply...
Defense Logistics Agency awarded a $11,853.45 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 capsules of 10 mg Vyvanse to be delivered by October 20, 2023. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. No set-aside provisions were applied to this contract action. Vyvanse is a prescription medication used to treat attention deficit hyperactivity disorder and binge eating disorder. This delivery order was...
The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $2,814 to Amerisourcebergen Drug Corporation for 100 capsules of 20 mg Vyvanse. The place of performance is Amerisourcebergen's facility in Conshohocken, Pennsylvania. The period of performance is August 16-17, 2023. Vyvanse is a central nervous system stimulant medication used to treat attention deficit hyperactivity disorder and binge eating disorder. This delivery order was issued under an...
The Defense Logistics Agency awarded a $431,000 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 100 Vyvanse 40mg capsules. Vyvanse is a medication used to treat attention deficit hyperactivity disorder and binge eating disorder. The place of performance for this order is Amerisourcebergen's facility in Conshohocken, Pennsylvania. The period of performance is August 3, 2023 through August 4, 2023. No subcontractors or set aside designations were...
The Defense Logistics Agency Troop Support Medical awarded a $1,578 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 capsules of 30 mg Vyvanse. The place of performance is Amerisourcebergen's facility in Conshohocken, Pennsylvania. The delivery order has a period of performance from July 31, 2023 through August 1, 2023 to supply the pharmaceutical product Vyvanse, which is used to treat attention deficit hyperactivity disorder. As the prime contractor,...
The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $1,300 to Amerisourcebergen Drug Corporation for 100 capsules of Vyvanse 30 mg. The place of performance will be Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is limited to one day, from July 31, 2023 through August 1, 2023. No major subcontractors or set aside designations were identified. The Defense Logistics Agency supports America's armed forces by...
The Defense Logistics Agency awarded a $2,586.06 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 capsules of the 30 mg Vyvanse medication. The delivery order was issued under an existing Prime Vendor contract vehicle to supply pharmaceutical products and services to DLA and DoD customers. Performance will take place in Conshohocken, Pennsylvania over a three day period concluding on August 29, 2023. The purpose of this order is to provide Vyvanse, a Schedule II...
The Defense Logistics Agency awarded a $3,401.80 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 capsules of 30 mg Vyvanse. The place of performance is Amerisourcebergen's Conshohocken, Pennsylvania facility. The one-day order runs from August 2 to August 3, 2023 to supply the attention deficit hyperactivity disorder medication to support DLA requirements. As the prime contractor, Amerisourcebergen will deliver the pharmaceutical products through its corporate...
The Defense Logistics Agency awarded a $1,082 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 100 capsules of 30 mg Vyvanse. The order is to be fulfilled by Amerisourcebergen's Conshohocken, Pennsylvania facility by July 18, 2023 in support of the Defense Logistics Agency's pharmaceutical procurement programs. No subcontractors or set aside designations were identified. The delivery order was issued against an existing DLA pharmaceutical supply vehicle and will...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB23FRE69
    Delivery Order

The Defense Logistics Agency awarded a firm fixed price delivery order valued at approximately $1,190 to Amerisourcebergen Drug Corporation for 4562055135 Vyvanse 30 mg capsules (100 count). The place of performance is Amerisourcebergen's corporate office and distribution center located in Conshohocken, Pennsylvania. The period of performance is September 5-6, 2023. This delivery order was issued against an existing DLA pharmaceutical supply vehicle to fulfill requirements for Vyvanse, a Schedule II controlled substance approved to treat attention deficit hyperactivity disorder and binge eating disorder. No set aside designation or subcontracting opportunities were identified.

Generated 12/20/23, 1:44 PM